US Stock MarketDetailed Quotes
GANX Gain Therapeutics
- 2.960
- +0.030+1.02%
Close May 3 16:00 ET
- 2.960
- 0.0000.00%
Post 19:52 ET
53.43MMarket Cap-1730P/E (TTM)
3.020High2.870Low96.02KVolume3.000Open2.930Pre Close280.55KTurnover0.60%Turnover RatioLossP/E (Static)18.05MShares5.61052wk High4.25P/B47.64MFloat Cap2.00052wk Low--Dividend TTM16.09MShs Float17.930Historical High--Div YieldTTM5.12%Amplitude2.000Historical Low2.921Avg Price1Lot Size
Gain Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -28.41%-18.87M | -44.97%-5.66M | -20.60%-3.97M | 0.59%-5.02M | -72.32%-4.22M | -18.81%-14.69M | 5.83%-3.9M | -50.03%-3.29M | -57.01%-5.05M | 12.90%-2.45M |
| Net income from continuing operations | -26.59%-22.27M | -1.06%-4.72M | -3.51%-4.72M | -51.18%-7.69M | -56.98%-5.14M | -26.64%-17.59M | -45.17%-4.67M | 2.26%-4.56M | -42.98%-5.09M | -33.55%-3.27M |
| Depreciation and amortization | 30.25%83.58K | 30.25%23.59K | 15.04%20.51K | 1.09%20.24K | 134.40%19.24K | 314.41%64.17K | 212.89%18.11K | 331.15%17.83K | 827.76%20.02K | 141.23%8.21K |
| Other non cash items | -85.24%-383.19K | 3.74%-135.7K | -377.36%-171.11K | --45.85K | ---122.24K | -506.01%-206.86K | -1,892.18%-140.97K | -77.12%-35.85K | ---- | ---- |
| Change In working capital | -70.81%442.23K | -512.96%-1.38M | -100.56%-5.18K | 624.31%1.37M | -10.39%457.47K | 559.35%1.51M | 124.14%334.02K | -45.83%931.5K | -54.51%-261.16K | 202.82%510.5K |
| -Change in receivables | -3,682.15%-130.07K | ---- | ---- | ---- | ---- | 105.73%3.63K | ---- | ---- | ---- | ---- |
| -Change in prepaid assets | 249.17%174.39K | -47.03%142.32K | -62.03%183.28K | 14.03%396.09K | 54.98%-547.3K | 76.64%-116.91K | 148.60%268.66K | -20.04%482.72K | 1,272.24%347.35K | -132.96%-1.22M |
| -Change in payables and accrued expense | -160.29%-643.16K | -109.23%-976.79K | -115.34%-46.1K | -32.87%-677.85K | -39.33%1.06M | 304.59%1.07M | 73.71%-466.85K | -74.17%300.59K | -6,375.99%-510.18K | 2,002.02%1.74M |
| -Change in other current assets | ---- | ---- | -101.55%-2.36K | ---2.35K | ---2.34K | ---- | ---- | 143.07%152.35K | --0 | --0 |
| -Change in other current liabilities | -107.11%-50.53K | ---- | ---- | ---- | ---- | 6.85%711.07K | ---- | ---- | ---- | ---- |
| -Change in other working capital | 829.45%1.09M | -1,131.70%-371.34K | -3,266.10%-140K | 1,781.46%1.65M | -196.73%-50.47K | -266.22%-149.65K | 30.07%-30.15K | 81.59%-4.16K | -145.36%-98.33K | 72.15%-17.01K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -28.41%-18.87M | -44.97%-5.66M | -20.60%-3.97M | 0.59%-5.02M | -72.32%-4.22M | -18.81%-14.69M | 5.83%-3.9M | -50.03%-3.29M | -57.01%-5.05M | 12.90%-2.45M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 169.19%10.22M | 2,247.65%3.14M | 17,002.33%1.93M | 120.45%3.05M | 27,026.26%2.11M | -15,582.52%-14.77M | 1,305.89%133.83K | 64.48%-11.41K | -66,066.32%-14.89M | 72.53%-7.83K |
| Net PPE purchase and sale | 87.09%-15.36K | 99.80%-19 | 98.86%-650 | 91.82%-3.64K | -41.15%-11.05K | -26.26%-118.95K | 15.32%-9.4K | -78.00%-57.18K | -97.98%-44.55K | 72.53%-7.83K |
| Net investment purchase and sale | 169.86%10.24M | 2,093.62%3.14M | 4,115.55%1.93M | 120.54%3.05M | --2.12M | ---14.66M | --143.23K | --45.77K | ---14.84M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 169.19%10.22M | 2,247.65%3.14M | 17,002.33%1.93M | 120.45%3.05M | 27,026.26%2.11M | -15,582.52%-14.77M | 1,305.89%133.83K | 64.48%-11.41K | -66,066.32%-14.89M | 72.53%-7.83K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 16,147.61%12.64M | 44,398.94%9.56M | 753.38%134.47K | 161,115.26%2.2M | 2,072.16%748.91K | -100.19%-78.77K | -121.69%-21.58K | -20.58K | 100.64%1.36K | -100.09%-37.97K |
| Net issuance payments of debt | -13.07%-89.07K | -4.62%-22.58K | -9.96%-22.63K | -1,732.13%-22.25K | 43.09%-21.61K | -258.86%-78.77K | 1.68%-21.58K | ---20.58K | --1.36K | ---37.97K |
| Net common stock issuance | --12.73M | --9.58M | --157.1K | --2.22M | --770.52K | --0 | --0 | --0 | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 16,147.61%12.64M | 44,398.94%9.56M | 753.38%134.47K | 161,115.26%2.2M | 2,072.16%748.91K | -100.19%-78.77K | -121.69%-21.58K | ---20.58K | 100.64%1.36K | -100.09%-37.97K |
| Net cash flow | ||||||||||
| Beginning cash position | -80.11%7.34M | -60.55%4.3M | -55.69%6.35M | -82.49%6.02M | -80.11%7.34M | 391.88%36.91M | -73.40%10.91M | -66.82%14.34M | -26.30%34.37M | 391.88%36.91M |
| Current changes in cash | 113.53%4M | 285.69%7.04M | 42.68%-1.9M | 101.11%221.11K | 45.39%-1.36M | -200.81%-29.55M | 8.99%-3.79M | -49.30%-3.32M | -477.38%-19.94M | -106.37%-2.49M |
| Effect of exchange rate changes | 2,152.38%488.4K | 113.78%483.25K | -36.43%-144.58K | 217.72%111.31K | 177.91%38.42K | -123.61%-23.8K | 250.42%226.05K | -407.61%-105.97K | -535.29%-94.56K | -147.77%-49.32K |
| End cash Position | 61.10%11.83M | 61.10%11.83M | -60.55%4.3M | -55.69%6.35M | -82.49%6.02M | -80.11%7.34M | -80.11%7.34M | -73.40%10.91M | -66.82%14.34M | -26.30%34.37M |
| Free cash flow | -27.48%-18.88M | -44.62%-5.66M | -18.56%-3.97M | 1.39%-5.03M | -72.22%-4.23M | -18.87%-14.81M | 5.86%-3.91M | -50.43%-3.35M | -57.29%-5.1M | 13.50%-2.46M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg